Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation Therapy
Top Cited Papers
- 1 May 2004
- journal article
- Published by Elsevier BV in European Urology
- Vol. 45 (5), 586-592
- https://doi.org/10.1016/j.eururo.2003.11.032
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinomaThe Prostate, 2002
- Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancerThe Prostate, 2002
- Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivinThe Prostate, 2001
- Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patientsThe Prostate, 2001
- Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samplesBritish Journal of Urology, 1997
- The Prognostic Value of Neuroendocrine Differentiation in Adenocarcinoma of the Prostate in Relation to Progression of Disease After Endocrine TherapyJournal of Urology, 1997
- Plasma Chromogranin a in Prostatic Carcinoma and Neuroendocrine TumorsJournal of Urology, 1997
- Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostateUrology, 1996
- Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostateThe Prostate, 1991
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984